Cirium: Radical Shifts in US Flight Schedules This Summer Reveal Why Airlines Need New Planning Tools to Stay Ahead of the Curve
27.10.2021 15:00:00 EEST | Business Wire | Press release
The new DiioTM Schedule Snapshot offering released by Cirium, the aviation analytics firm, reveals how planning by the major US airlines changed over the summer, with 20% of flights being removed from their schedule for September.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211027005581/en/
The September flight schedules as published by American Airlines, Delta Air Lines, Southwest, and United Airlines initially in May compared with the revised plan published four months later. (Graphic: Business Wire)
At the start of May 2021, the plan for what carriers would fly in September was more or less in line with pre-pandemic levels in 2019. By the time they came to fly the September schedule, American Airlines, Delta Air Lines, Southwest and United Airlines had significantly cut back their flights.
Airlines are now making major changes to the way they schedule flights—publishing or removing them much closer to the date of departure as they struggle with the uncertainties brought on by the pandemic.
Prior to the pandemic schedules would remain fairly stable over a season, with few changes—positive or negative—as the plan was refined.
Only 3% of flights were removed from the September schedule in 2019 compared with the plan published in May that year.
The new Diio Schedule Snapshot web-based tool enables airlines and airports to track changes to the flights being scheduled at different points in time. It provides much more detail on schedule changes than has been done in the past.
“In today's environment where travel restrictions and vaccination programs are significantly impacting flight schedules, airlines have had to adapt and issue changes to their schedules frequently and much closer to the day of departure. The traditional methods used to analyze demand need to be more dynamic,” said Kevin O’Toole, Chief Strategy Officer at Cirium.
“Using Diio Schedules Snapshot, airlines and airports can understand schedule changes over time, optimize future schedules, build stronger models for planning and revenue management, and optimize yield through trend analysis.”
The analysis of the major US airlines evidences the radical shift in the summer flight schedule and the impact that the pandemic has had on the variance in airline planning year-over-year.
Understanding and comparing changes to the published flight schedule over time as it gets closer to actual departure, enables analysts to stay ahead of the curve, and provides new insights for planning and revenue management.
Reviewing historical data by publication date also provides insights on airline and airport strategies in an uncertain world.
Diio Schedule Snapshot is part of the unrivaled Cirium Diio suite of products for airline planning. The suite includes Diio Mi, SRS AnalyserTM, Cirium Scenario Planner, and Diio Traffic and Fares.
The new tool integrates with Cirium Diio Mi or SRS Analyser and is the first of many more new tools in the Cirium pipeline to help airlines optimize their schedules and find new revenue opportunities.
More information on Diio Schedule Snapshot can be found at https://cirium.com/products/views/diio-schedule-snapshot
-End-
For further information please visit https://www.cirium.com and follow Cirium updates via LinkedIn and Twitter.
About Cirium
Cirium brings together powerful data and analytics to keep the world moving. Delivering insight, built from decades of experience in the sector, enabling travel companies, aircraft manufacturers, airports, airlines and financial institutions, among others, to make logical and informed decisions which shape the future of travel, growing revenues and enhancing customer experiences. Cirium is part of RELX, a global provider of information-based analytics and decision tools for professional and business customers. The shares of RELX PLC are traded on the London, Amsterdam and New York Stock Exchanges using the following ticker symbols: London: REL; Amsterdam: REN; New York: RELX.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211027005581/en/
Contact information
For media enquiries please contact:
Mike Arnot, Juliett Alpha via cirium@juliettalpha.com
or the Cirium media team at media@cirium.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Industrial Decarbonization: Calderion, WenCo and Terravent Invest in Graforce to Scale Plasma Pyrolysis Globally25.2.2026 09:07:00 EET | Press release
The investor consortium comprising the Paris-based Next Generation Fuels Industrial & Technological fund Calderion (Audacia), alongside infrastructure developer Terravent and WenCo Family Office, announces the closing of a strategic double-digit million-euro financing round for Berlin-based Graforce GmbH. The investment is dedicated to the industrial scale-up of Graforce’s proprietary plasma pyrolysis technology, addressing the growing global demand for cost-efficient low-carbon hydrogen, syngas, and carbon removal solutions that are compatible with existing industrial infrastructures. Disruptive alternative to conventional processes Graforce’s technology aims at replacing CO₂-intensive legacy routes such as steam reforming and classical gasification. By applying plasma to methane, biogas, flare gas, and landfill gas, the process converts these streams into their valuable molecular components instead of emitting them. The result is a high-efficiency production of clean hydrogen and syn
Mevion Medical Systems Announces CE Marking of the MEVION S250-FIT™ Proton Therapy System, Expanding Global Access to Compact Proton Therapy25.2.2026 09:00:00 EET | Press release
Mevion Medical Systems, the global leader in compact proton therapy, today announced that the MEVION S250-FIT Proton Therapy System has successfully completed the conformity assessment process and has received CE Marking under Regulation (EU) 2017/745 (EU MDR). This regulatory milestone enables the marketing, sale, and clinical use of the MEVION S250-FIT system throughout the European Union, building on the system’s existing U.S. FDA 510(k) clearance granted in September 2025. The MEVION S250-FIT is the first and only proton therapy system designed to fit into a standard radiation therapy vault. By enabling cancer centers to use their existing infrastructure, the MEVION S250-FIT dramatically reduces the cost, complexity, and timeline traditionally associated with proton therapy adoption. This opens a new pathway for hospitals and cancer centers across Europe to bring advanced proton treatment to their patients. “With both FDA clearance and CE Marking now in hand, the MEVION S250-FIT is
Bureau Veritas: Sector-Leading Organic Revenue Growth of 6.5% in FY 202525.2.2026 08:30:00 EET | Press release
Bureau Veritas (BOURSE:BVI): 2025 key figures1 › Full-year revenue of EUR 6,466.4 million, up 6.5% organically (with 6.3% organic growth in Q4). At constant currency, the growth was up 7.3% year-on-year and up 3.6% on a reported basis, › Adjusted operating profit of EUR 1,052.9 million, up 5.7% versus EUR 996.2 million in FY 2024, representing an adjusted operating margin of 16.3%, up 32 basis points year-on-year and up 51 basis points at constant currency, › Operating profit of EUR 992.4 million, up 6.3% versus EUR 933.4 million in FY 2024, › Adjusted net profit of EUR 631.4 million, up 1.7% versus EUR 620.7 million in FY 2024, › Adjusted EPS stood at EUR 1.42 in 2025, with a 2.8% increase versus FY 2024 (EUR 1.38 per share) and up 9.2% at constant currency, › Attributable net profit of EUR 588.0 million, up 3.3% versus EUR 569.4 million in FY 2024, › Free Cash Flow of EUR 824.2 million, up 3.9% organically and up 2.6% at constant currency, and cash conversion of 107%2, › Adjusted net
Azafaros Announces Publication of Preclinical Efficacy Data with Nizubaglustat in GM2 Gangliosidosis25.2.2026 08:00:00 EET | Press release
Azafaros, a company aiming to become a leader in lysosomal storage disorders (LSDs), focused on addressing especially neurological symptoms, today announced the publication of proof-of-concept preclinical data with its lead product, nizubaglustat, in GM2 gangliosidosis. The data, published in the 7 January issue of the Journal of Inherited Metabolic Disease in collaboration with the laboratory of Dr. Jagdeep Walia, Department of Pediatrics, Queen's University, Kingston, Canada, reinforce nizubaglustat’s potential to address unmet needs in rare LSDs and build on existing preclinical and clinical evidence. The preclinical study tested nizubaglustat in a mouse model in Sandhoff disease, a form of GM2 gangliosidosis with no approved treatments—alongside healthy control subjects. The research assessed how the drug’s exposure relates to its effects in the brain, demonstrating a significant increase in both survival (22%; 26 days) and assessments of movement and behavior at 16 weeks versus un
Galderma Announces Triple Approval of New State-of-the-Art Restylane ® Syringe in the EU, the U.S., and Canada, Reaffirming the Company’s Position at the Forefront of Injectable Aesthetics25.2.2026 08:00:00 EET | Press release
Galderma (SIX: GALD), today announced that regulatory authorities in the EU, the U.S., and Canada have approved a new state-of-the-art syringe for use with its NASHA® lidocaine range of Restylane products in multiple facial indications including the cheeks, nose, chin, jawline, tear troughs, nasolabial folds, marionette lines, as well as in the hands.1-3 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260224651688/en/ The syringe features a next-generation ergonomic design that enhances precision and control; includes an optimized syringe-needle connection with the new Terumo K-Pack Enhance™ needle; and offers a premium color-coded packaging and syringe design to support easy range navigation for practitioners.4-7, 9,10 It sets a new standard in Injectable Aesthetic devices and demonstrates Galderma’s unwavering commitment to driving innovation to meet the needs of both practitioners and patients. “Developing this new syringe
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom